Literature DB >> 27323588

LOW BONE MINERAL DENSITY AMONG PATIENTS WITH NEWLY DIAGNOSED RHEUMATOID ARTHRITIS.

Shafique Rehman Arain, Amir Riaz, Lubna Nazir, Tahira Perveen Umer, Tabe Rasool.   

Abstract

BACKGROUND: Osteoporosis is an early and common feature in rheumatoid arthritis. Apart from other manifestations, Osteoporosis is an extra-articular manifestation of rheumatoid arthritis whichmay result in increased risk of fractures, morbidity mortality, and associated healthcare costs. This study evaluates bone mineral density changes in patients withrheumatoid arthritis of recent-onset.
METHODS: This cross sectional descriptive study was conducted in the Rheumatology Department of a tertiary care hospital in Karachi. Data was collected from 76 patients presenting with seropositive or seronegative rheumatoid arthritis. Bone mineral density of these patients measured at lumbar spine and hip by using dual energy x-ray absorptiometrys can. Variables like age, gender, BMI, menstrual status, disease duration, erythrocyte sedimentation rate, vitamin D level, clinical disease activity index and seropositivity for rheumatoid arthritis were measured along with outcome variables.
RESULTS: A total of 104 patients fulfilling inclusion criteria were registered with 28 excluded from study. A mong the remaining 76 patients, 68 (89.50%) were female, with mean age of patients (with low bone mineral density) as 50.95 ± 7.87 years. Nineteen (25%) patients had low bone mineral density, 68.52% had low BMD at spine while 10.52% at hip and 21.05% at spine and hip both. Low bone mineral density was found higher in patients with seronegative 7 (50%) as compared to seropositive patients 12 (19.4%) (p-value 0.017), whereas low bone mineral d ensity was found higher 12 (70.6%) among post-menopausal women.
CONCLUSION: Low BMD was found in 25% of patients at earlier stage of the rheumatoid arthritis with seropositivity, age and menopausal status as significant risk factors.

Entities:  

Mesh:

Year:  2016        PMID: 27323588

Source DB:  PubMed          Journal:  J Ayub Med Coll Abbottabad        ISSN: 1025-9589


  6 in total

1.  The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis-A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study.

Authors:  Shan-Fu Yu; Jia-Feng Chen; Ying-Chou Chen; Yu-Wei Wang; Chung-Yuan Hsu; Han-Ming Lai; Hsiao-Ru He; Chi-Hua Ko; Wen-Chan Chiu; Tien-Tsai Cheng
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.

Authors:  Yukio Nakamura; Takako Suzuki; Tomohiko Yoshida; Hideshi Yamazaki; Hiroyuki Kato
Journal:  Nutrients       Date:  2017-04-26       Impact factor: 5.717

3.  The Influence of Menopause and Inflammation on Redox Status and Bone Mineral Density in Patients with Rheumatoid Arthritis.

Authors:  Aleksandra Stojanovic; Mirjana Veselinovic; Nevena Draginic; Marina Rankovic; Marijana Andjic; Jovana Bradic; Sergey Bolevich; Aleksandra Antovic; Vladimir Jakovljevic
Journal:  Oxid Med Cell Longev       Date:  2021-01-07       Impact factor: 6.543

4.  Sarcopenia May Be a Risk Factor for Osteoporosis in Chinese Patients with Rheumatoid Arthritis.

Authors:  Li Lian; Jian-Xiong Wang; Yue-Chen Xu; He-Xiang Zong; Yu-Zhu Teng; Sheng-Qian Xu
Journal:  Int J Gen Med       Date:  2022-02-23

5.  Prevalence and risk factors for bone loss in rheumatoid arthritis patients from South China: modeled by three methods.

Authors:  Zhuoran Hu; Lei Zhang; Zhiming Lin; Changlin Zhao; Shuiming Xu; He Lin; Jiejing Zhang; Wenjie Li; Yongliang Chu
Journal:  BMC Musculoskelet Disord       Date:  2021-06-12       Impact factor: 2.362

6.  Male patients with rheumatoid arthritis have an increased risk of osteoporosis: Frequency and risk factors.

Authors:  Seong-Min Kweon; Dong Hyun Sohn; Ji-Heh Park; Jung Hee Koh; Eun-Kyoung Park; Han-Na Lee; Keunyoung Kim; Yunkyung Kim; Geun-Tae Kim; Seung-Geun Lee
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.